BR112012001653A2 - partícula de vetor lentiviral, genoma de vetor lentiviral pseudotipado em um envelope, sistema de acondicionamento de vetor lentiviral para produzir uma partícula de vetor lentiviral pesudotipado, célula, molécula de ácido nucleico isolada, vetor de expressão, célula hospedeira, métodos para fazer uma partícula de vetor lentiviral, e para distribuir partículas de vetor lentiviral para células invitro, e vacina terapêutica ou profilática - Google Patents

partícula de vetor lentiviral, genoma de vetor lentiviral pseudotipado em um envelope, sistema de acondicionamento de vetor lentiviral para produzir uma partícula de vetor lentiviral pesudotipado, célula, molécula de ácido nucleico isolada, vetor de expressão, célula hospedeira, métodos para fazer uma partícula de vetor lentiviral, e para distribuir partículas de vetor lentiviral para células invitro, e vacina terapêutica ou profilática

Info

Publication number
BR112012001653A2
BR112012001653A2 BR112012001653A BR112012001653A BR112012001653A2 BR 112012001653 A2 BR112012001653 A2 BR 112012001653A2 BR 112012001653 A BR112012001653 A BR 112012001653A BR 112012001653 A BR112012001653 A BR 112012001653A BR 112012001653 A2 BR112012001653 A2 BR 112012001653A2
Authority
BR
Brazil
Prior art keywords
lentiviral vector
particle
vector
cell
lentiviral
Prior art date
Application number
BR112012001653A
Other languages
English (en)
Portuguese (pt)
Inventor
Derek D Sloan
James M Allen
jin zhong Li
Neal S Van Hoeven
Thomas W Dubensky Jr
Original Assignee
Immune Design Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42727669&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012001653(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immune Design Corp filed Critical Immune Design Corp
Publication of BR112012001653A2 publication Critical patent/BR112012001653A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001188—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001191—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001192—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001194—Prostate specific antigen [PSA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001195—Prostate specific membrane antigen [PSMA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/50—Colon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36145—Special targeting system for viral vectors
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BR112012001653A 2009-07-24 2010-07-22 partícula de vetor lentiviral, genoma de vetor lentiviral pseudotipado em um envelope, sistema de acondicionamento de vetor lentiviral para produzir uma partícula de vetor lentiviral pesudotipado, célula, molécula de ácido nucleico isolada, vetor de expressão, célula hospedeira, métodos para fazer uma partícula de vetor lentiviral, e para distribuir partículas de vetor lentiviral para células invitro, e vacina terapêutica ou profilática BR112012001653A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22849109P 2009-07-24 2009-07-24
PCT/US2010/042870 WO2011011584A1 (en) 2009-07-24 2010-07-22 Lentiviral vectors pseudotyped with a sindbis virus envelope glycoprotein

Publications (1)

Publication Number Publication Date
BR112012001653A2 true BR112012001653A2 (pt) 2016-11-08

Family

ID=42727669

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012001653A BR112012001653A2 (pt) 2009-07-24 2010-07-22 partícula de vetor lentiviral, genoma de vetor lentiviral pseudotipado em um envelope, sistema de acondicionamento de vetor lentiviral para produzir uma partícula de vetor lentiviral pesudotipado, célula, molécula de ácido nucleico isolada, vetor de expressão, célula hospedeira, métodos para fazer uma partícula de vetor lentiviral, e para distribuir partículas de vetor lentiviral para células invitro, e vacina terapêutica ou profilática

Country Status (27)

Country Link
US (3) US20110064763A1 (cg-RX-API-DMAC7.html)
EP (2) EP2456786B2 (cg-RX-API-DMAC7.html)
JP (4) JP2013500015A (cg-RX-API-DMAC7.html)
KR (1) KR101790187B1 (cg-RX-API-DMAC7.html)
CN (1) CN102482329B (cg-RX-API-DMAC7.html)
AU (1) AU2010276194B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012001653A2 (cg-RX-API-DMAC7.html)
CA (1) CA2768938C (cg-RX-API-DMAC7.html)
CY (1) CY1121159T1 (cg-RX-API-DMAC7.html)
DK (2) DK2456786T4 (cg-RX-API-DMAC7.html)
EA (1) EA032403B1 (cg-RX-API-DMAC7.html)
ES (2) ES2702274T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20140327T4 (cg-RX-API-DMAC7.html)
HU (1) HUE043032T2 (cg-RX-API-DMAC7.html)
IL (1) IL217679A (cg-RX-API-DMAC7.html)
LT (1) LT2770061T (cg-RX-API-DMAC7.html)
ME (1) ME01720B (cg-RX-API-DMAC7.html)
MX (1) MX2012001075A (cg-RX-API-DMAC7.html)
NZ (1) NZ597804A (cg-RX-API-DMAC7.html)
PL (2) PL2770061T3 (cg-RX-API-DMAC7.html)
PT (2) PT2456786E (cg-RX-API-DMAC7.html)
RS (2) RS53257B2 (cg-RX-API-DMAC7.html)
SG (1) SG177744A1 (cg-RX-API-DMAC7.html)
SI (2) SI2456786T2 (cg-RX-API-DMAC7.html)
SM (2) SMT201800656T1 (cg-RX-API-DMAC7.html)
TR (1) TR201819229T4 (cg-RX-API-DMAC7.html)
WO (1) WO2011011584A1 (cg-RX-API-DMAC7.html)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120201794A1 (en) * 2009-07-15 2012-08-09 Calimmune Inc. Dual vector for inhibition of human immunodeficiency virus
AU2012217723A1 (en) * 2011-02-15 2013-08-29 Immune Design Corp. Methods for enhancing immunogen specific immune responses by vectored vaccines
NZ616304A (en) * 2011-04-08 2016-01-29 Immune Design Corp Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
EP2809345A4 (en) * 2012-02-03 2015-11-25 Univ Emory IMMUNOSTIMULATING COMPOSITIONS, PARTICLES THEREFOR, AND USES THEREFOR
WO2013148327A1 (en) 2012-03-26 2013-10-03 The Regents Of The University Of California Nipah virus envelope psuedotyped lentiviruses and methods of their use
US8323662B1 (en) * 2012-03-30 2012-12-04 Immune Design Corp. Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein
AU2013237900B2 (en) * 2012-03-30 2017-07-27 Immune Design Corp. Lentiviral vector particles having improved transduction efficiency for cells expressing DC- SIGN
US9713635B2 (en) * 2012-03-30 2017-07-25 Immune Design Corp. Materials and methods for producing improved lentiviral vector particles
SMT201800368T1 (it) 2012-05-16 2018-09-13 Immune Design Corp Vaccini per l'infezione da virus-2 herpes simplex
WO2014109728A1 (en) * 2013-01-11 2014-07-17 The Scripps Research Institute Methods and compositions for enchancing transduction efficiency of retroviral vectors
GB201308772D0 (en) * 2013-05-15 2013-06-26 Imp Innovations Ltd Vectors
BR112016020688B1 (pt) 2014-03-09 2024-01-30 The Trustees Of The University Of Pennsylvania Vetores virais recombinantes, vírus adenoassociado recombinante, composição farmacêutica, bem como uso dos mesmos
MX2017000630A (es) 2014-07-15 2017-04-27 Immune Design Corp Regimenes de sensibilización-refuerzo con un adyuvante de agonista tlr4 y un vector lentiviral.
JP6760964B2 (ja) * 2015-01-21 2020-09-23 コーネル ユニバーシティ 異常ヘモグロビン症の予防及び治療のためのウイルスベクター
CA2974903A1 (en) * 2015-01-26 2016-08-04 Fate Therapeutics, Inc. Cells with increased immuno-regulatory properties and methods for their use and manufacture
RU2017132190A (ru) * 2015-03-18 2019-04-18 Омнисайт Гибридные белки, содержащие модифицированные поверхностные гликопротеины альфавируса и опухолеассоциированный антиген, и способы, связанные с ними
CN108026593A (zh) 2015-05-18 2018-05-11 卡琳缪恩股份有限公司 区分hiv-1与慢病毒载体的方法
KR20180043800A (ko) 2015-09-09 2018-04-30 이뮨 디자인 코포레이션 Ny-eso-1 특이적 tcrs 및 그의 사용 방법
EA201890861A1 (ru) 2015-11-09 2018-10-31 Иммьюн Дизайн Корп. Композиции, содержащие лентивирусные векторы, экспрессирующие il-12, и способы их применения
KR20180074699A (ko) 2015-11-09 2018-07-03 이뮨 디자인 코포레이션 이종 핵산을 발현하는 rna 레플리콘의 발현 및 투여를 위한 레트로바이러스 벡터
CN109154005A (zh) 2016-02-23 2019-01-04 免疫设计股份有限公司 多基因组逆转录病毒载体制剂及用于产生及使用该制剂的方法和系统
WO2017152042A2 (en) * 2016-03-04 2017-09-08 New York University Virus vectors expressing multiple epitopes of tumor associated antigens for inducing antitumor immunity
SG11201808457PA (en) 2016-04-15 2018-10-30 Alpine Immune Sciences Inc Icos ligand variant immunomodulatory proteins and uses thereof
AU2017248830B2 (en) 2016-04-15 2023-03-09 Alpine Immune Sciences, Inc. CD80 variant immunomodulatory proteins and uses thereof
EP3235908A1 (en) 2016-04-21 2017-10-25 Ecole Normale Superieure De Lyon Methods for selectively modulating the activity of distinct subtypes of cells
EP3235828A1 (en) * 2016-04-21 2017-10-25 Genethon Stable pseudotyped lentiviral particles and uses thereof
WO2018022945A1 (en) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Cd112 variant immunomodulatory proteins and uses thereof
EP3491013A1 (en) 2016-07-28 2019-06-05 Alpine Immune Sciences, Inc. Cd155 variant immunomodulatory proteins and uses thereof
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
EP3872180A1 (en) 2016-10-20 2021-09-01 Alpine Immune Sciences, Inc. Secretable variant immunomodulatory proteins and engineered cell therapy
WO2018148180A2 (en) 2017-02-07 2018-08-16 Immune Design Corp. Materials and methods for identifying and treating cancer patients
JP2020511144A (ja) 2017-03-16 2020-04-16 アルパイン イミューン サイエンシズ インコーポレイテッド Pd−l2バリアント免疫調節タンパク質及びその使用
FI3596116T3 (fi) 2017-03-16 2023-11-09 Alpine Immune Sciences Inc Immunomodulatorisia pd-l1-varianttiproteiineja ja niiden käyttöjä
MX2019010887A (es) 2017-03-16 2019-10-15 Alpine Immune Sciences Inc Proteinas inmunomoduladoras de cb80 variante y usos de estas.
US11576872B2 (en) 2017-05-08 2023-02-14 Flagship Pioneering Innovations V, Inc. Compositions for facilitating membrane fusion and uses thereof
JP7282760B2 (ja) 2017-10-18 2023-05-29 アルパイン イミューン サイエンシズ インコーポレイテッド バリアントicosリガンド免疫調節タンパク質ならびに関連する組成物および方法
SG11202006148UA (en) 2018-01-03 2020-07-29 Alpine Immune Sciences Inc Multi-domain immunomodulatory proteins and methods of use thereof
US11116833B2 (en) * 2018-02-08 2021-09-14 George Mason University Method and system for inactivating virus infectivity for producing live-attenuated vaccines
EP3788070A4 (en) 2018-04-30 2022-03-09 The Children's Hospital Of Philadelphia COMPOSITIONS AND METHODS OF HEMOGLOBIN PRODUCTION
WO2019241758A1 (en) 2018-06-15 2019-12-19 Alpine Immune Sciences, Inc. Pd-1 variant immunomodulatory proteins and uses thereof
CA3105953A1 (en) 2018-07-09 2020-01-16 Flagship Pioneering Innovations V, Inc. Fusosome compositions and uses thereof
US12241079B2 (en) 2018-09-14 2025-03-04 The Children's Hospital Of Philadelphia Compositions and methods for hemoglobin production
KR20210131991A (ko) 2018-11-14 2021-11-03 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 구획-특이적 카고 전달을 위한 조성물 및 방법
WO2020104694A1 (en) * 2018-11-23 2020-05-28 Vira Therapeutics Gmbh Vsv chimeric vectors
CN113727998A (zh) 2018-11-30 2021-11-30 高山免疫科学股份有限公司 Cd86变体免疫调节蛋白及其用途
JP7495435B2 (ja) 2019-06-14 2024-06-04 ザ ジェイ. デビッド グラッドストーン インスティテューツ、 ア テスタメンタリー トラスト エスタブリッシュド アンダー ザ ウィル オブ ジェイ. デビッド グラッドストーン 治療用干渉粒子による免疫不全ウイルス感染を処置するための組成物及び方法
US20220307050A1 (en) * 2019-08-01 2022-09-29 The Regents Of The University Of California Non-viral transgenesis
CN110982842B (zh) * 2019-12-31 2023-04-18 山西大学 一种慢病毒表达载体的设计及应用
JP2023535163A (ja) * 2020-07-15 2023-08-16 アンスティテュ・パストゥール Sars-cov-2免疫原性組成物、ワクチン、及び方法
JP2024532963A (ja) 2021-04-08 2024-09-11 サナ バイオテクノロジー,インコーポレイテッド Cd8特異的抗体コンストラクト及びその組成物
AU2022377374A1 (en) * 2021-10-25 2024-05-02 Genvivo, Inc. Compositions and methods for therapeutic or vaccine delivery
EP4504979A1 (en) * 2022-04-05 2025-02-12 Bio-Rad Laboratories, Inc. Analysis of viral particles by digital assay
AU2023269134A1 (en) 2022-05-09 2024-12-12 Regeneron Pharmaceuticals, Inc. Vectors and methods for in vivo antibody production
WO2023240124A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Pseudotyped viral particles for targeting tcr-expressing cells
US12502437B2 (en) 2023-11-15 2025-12-23 Genvivo, Inc. Compositions and methods for therapeutic delivery
CN122012416A (zh) * 2026-04-14 2026-05-12 山东丽山生物科技有限公司 一种提高慢病毒滴度的方法

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
US4569794A (en) 1984-12-05 1986-02-11 Eli Lilly And Company Process for purifying proteins and compounds useful in such process
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
CA1283827C (en) 1986-12-18 1991-05-07 Giorgio Cirelli Appliance for injection of liquid formulations
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4937190A (en) 1987-10-15 1990-06-26 Wisconsin Alumni Research Foundation Translation enhancer
ATE112314T1 (de) 1988-05-17 1994-10-15 Lubrizol Genetics Inc Pflanzliches ubiquitinpromotorsystem.
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
US5298420A (en) 1990-08-03 1994-03-29 Tanox Biosystems, Inc. Antibodies specific for isotype specific domains of human IgM and human IgG expressed or the B cell surface
TW279133B (cg-RX-API-DMAC7.html) 1990-12-13 1996-06-21 Elan Med Tech
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
WO1994006920A1 (en) 1992-09-22 1994-03-31 Medical Research Council Recombinant viruses displaying a nonviral polypeptide on their external surface
US6534051B1 (en) 1992-11-20 2003-03-18 University Of Medicine And Dentistry Of New Jersey Cell type specific gene transfer using retroviral vectors containing antibody-envelope fusion proteins and wild-type envelope fusion proteins
US5279552A (en) 1993-01-11 1994-01-18 Anton Magnet Intradermal injection device
US5997501A (en) 1993-11-18 1999-12-07 Elan Corporation, Plc Intradermal drug delivery device
WO1996017072A2 (en) 1994-11-30 1996-06-06 Chiron Viagene, Inc. Recombinant alphavirus vectors
US5660835A (en) 1995-02-24 1997-08-26 East Carolina University Method of treating adenosine depletion
US6261554B1 (en) 1995-07-25 2001-07-17 Introgene B.V. Compositions for targeted gene delivery
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5910434A (en) 1995-12-15 1999-06-08 Systemix, Inc. Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant
FR2747046B1 (fr) 1996-04-05 1998-06-19 Univ Paris Curie Nouveaux vaccins issus de plasmovirus
EP0961830A1 (en) 1997-01-29 1999-12-08 Neurosearch A/S EXPRESSION VECTORS AND METHODS FOR $i(IN VIVO) EXPRESSION OF THERAPEUTIC POLYPEPTIDES
US6432699B1 (en) * 1997-03-28 2002-08-13 New York University Viral vectors having chimeric envelope proteins containing the IgG-binding domain of protein A
US6531123B1 (en) 1997-05-01 2003-03-11 Lung-Ji Chang Lentiviral vectors
WO1999013905A1 (en) 1997-09-18 1999-03-25 The Trustees Of The University Of Pennsylvania Receptor-binding pocket mutants of influenza a virus hemagglutinin for use in targeted gene delivery
ZA988446B (en) 1997-09-18 2000-03-22 Res Dev Foundation Production of vaccines using arthropod vectored viruses.
US6218181B1 (en) 1998-03-18 2001-04-17 The Salk Institute For Biological Studies Retroviral packaging cell line
US7078483B2 (en) 1998-04-29 2006-07-18 University Of Southern California Retroviral vectors including modified envelope escort proteins
DE69941049D1 (de) * 1998-05-22 2009-08-13 Oxford Biomedica Ltd Retrovirales verabreichungssystem
AU3893000A (en) * 1999-03-16 2000-10-04 Dana-Farber Cancer Institute, Inc. Lentiviral vector system for high quantity screening
CA2373300C (en) * 1999-04-14 2012-02-21 Chiron Corporation Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
EP1046651A1 (en) 1999-04-19 2000-10-25 Koninklijke Universiteit Nijmegen Composition and method for modulating dendritic cell-T interaction
CA2392010A1 (en) 1999-08-27 2001-03-08 Regents Of The University Of California Use of lentiviral vectors for antigen presentation in dendritic cells
ATE454901T1 (de) 1999-10-13 2010-01-15 Novartis Vaccines & Diagnostic Verfahren zur erhaltung zellimmuneantworten gegen proteinen
US6569143B2 (en) 1999-10-14 2003-05-27 Becton, Dickinson And Company Method of intradermally injecting substances
US6494865B1 (en) 1999-10-14 2002-12-17 Becton Dickinson And Company Intradermal delivery device including a needle assembly
US7241275B2 (en) 1999-10-14 2007-07-10 Becton, Dickinson And Company Intradermal needle
US20020193740A1 (en) 1999-10-14 2002-12-19 Alchas Paul G. Method of intradermally injecting substances
US6776776B2 (en) 1999-10-14 2004-08-17 Becton, Dickinson And Company Prefillable intradermal delivery device
US6627442B1 (en) * 2000-08-31 2003-09-30 Virxsys Corporation Methods for stable transduction of cells with hiv-derived viral vectors
JP2004532012A (ja) * 2001-03-02 2004-10-21 メルク エンド カムパニー インコーポレーテッド ウイルスリポーター粒子
CA2449589A1 (en) * 2001-06-08 2002-12-19 Dnavec Research Inc. Gene transfer into primate embryonic stem cells using vsv-g pseudotyped simian immunodeficiency virus vector
CA2457282C (en) 2001-09-13 2015-01-13 California Institute Of Technology Method for expression of small antiviral rna molecules within a cell
US7737124B2 (en) 2001-09-13 2010-06-15 California Institute Of Technology Method for expression of small antiviral RNA molecules with reduced cytotoxicity within a cell
EP1425400B1 (en) 2001-09-13 2016-11-02 California Institute Of Technology Method for producing transgenic animals
US7195916B2 (en) 2001-09-13 2007-03-27 California Institute Of Technology Method for expression of small antiviral RNA molecules within a cell
WO2003041763A2 (en) 2001-11-14 2003-05-22 Medical Instill Technologies, Inc. Intradermal delivery device and method
EP1478428B1 (en) 2002-02-04 2009-07-15 Becton, Dickinson and Company Device and method for delivering or withdrawing a substance through the skin
US6780171B2 (en) 2002-04-02 2004-08-24 Becton, Dickinson And Company Intradermal delivery device
US7115108B2 (en) 2002-04-02 2006-10-03 Becton, Dickinson And Company Method and device for intradermally delivering a substance
US7047070B2 (en) 2002-04-02 2006-05-16 Becton, Dickinson And Company Valved intradermal delivery device and method of intradermally delivering a substance to a patient
KR101002955B1 (ko) * 2002-04-26 2010-12-21 인스티튜트 클레이톤 드 라 리쎄르셰 개선된 키메라 당단백질 및 슈도타입 렌티바이러스 벡터
US7455833B2 (en) 2002-07-15 2008-11-25 Board Of Regents, The University Of Texas System Methods and compositions for treating viral infections using antibodies and immunoconjugates to aminophospholipids
WO2004016280A1 (ja) 2002-08-16 2004-02-26 Japan Science And Technology Agency 組換えbcgワクチン
WO2004056966A2 (en) 2002-12-18 2004-07-08 Salk Institute For Biological Studies Methods of inhibiting gene expression by rna interference
US7090837B2 (en) 2003-01-21 2006-08-15 The Salk Institute For Biological Studies Compositions and methods for tissue specific targeting of lentivirus vectors
US20050214318A1 (en) 2003-10-23 2005-09-29 Nmk Research, Llc Immunogenic composition and method of developing a vaccine based on fusion protein
US7108679B2 (en) 2004-03-11 2006-09-19 Becton, Dickinson And Company Intradermal syringe and needle assembly
US20070275873A1 (en) * 2004-04-29 2007-11-29 Heidner Hans W Methods and Compositions Comprising Protein L Immunoglobulin Binding Domains for Cell-Specific Targeting
WO2005118802A2 (en) 2004-06-03 2005-12-15 The Regents Of The University Of California Targeting pseudotyped retroviral vectors
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
WO2006031996A2 (en) * 2004-09-14 2006-03-23 University Of Pittsburgh Of The Commonwealth System Of Higher Education Targeting viruses using a modified sindbis glycoprotein
RU2007134371A (ru) * 2005-02-16 2009-03-27 Лентиджен Корпорейшн (Us) Лентивирусные векторы и их применение
EP2963118B1 (en) 2005-06-01 2017-08-09 California Institute of Technology Method of targeted gene delivery using viral vectors
WO2008011636A2 (en) * 2006-07-21 2008-01-24 California Institute Of Technology Targeted gene delivery for dendritic cell vaccination
EP2468300B1 (en) 2006-09-26 2017-12-20 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US8563523B2 (en) 2007-09-07 2013-10-22 University Of Georgia Research Foundation, Inc. Synthetic lipid A derivative
LT2222861T (lt) 2007-12-11 2018-03-26 The University Of North Carolina At Chapel Hill Retrovirusiniai vektoriai modifikuoti polipurino atkarpa

Also Published As

Publication number Publication date
PT2456786E (pt) 2014-03-25
SI2456786T2 (sl) 2017-08-31
HK1201557A1 (en) 2015-09-04
JP6701280B2 (ja) 2020-05-27
RS53257B2 (sr) 2018-06-29
CA2768938C (en) 2019-05-14
PT2770061T (pt) 2018-12-24
MX2012001075A (es) 2012-05-22
TR201819229T4 (tr) 2019-01-21
PL2456786T3 (pl) 2014-06-30
SI2456786T1 (sl) 2014-05-30
EP2770061B1 (en) 2018-10-24
LT2770061T (lt) 2018-12-27
SMT201400041B (it) 2014-05-07
US20160076055A1 (en) 2016-03-17
SMT201800656T1 (it) 2019-01-11
US8187872B2 (en) 2012-05-29
PL2456786T5 (pl) 2017-10-31
HUE043032T2 (hu) 2019-07-29
RS58042B1 (sr) 2019-02-28
ME01720B (me) 2014-09-20
US20120039932A1 (en) 2012-02-16
ES2455544T5 (es) 2017-08-16
EP2770061A1 (en) 2014-08-27
EP2456786B2 (en) 2017-04-19
EP2456786B1 (en) 2014-01-08
EA032403B1 (ru) 2019-05-31
HRP20181996T1 (hr) 2019-03-22
CY1121159T1 (el) 2020-05-29
DK2770061T3 (en) 2019-01-07
JP2018198616A (ja) 2018-12-20
EA201270191A1 (ru) 2012-12-28
JP6170952B2 (ja) 2017-07-26
JP2017060535A (ja) 2017-03-30
RS53257B (sr) 2014-08-29
CN102482329B (zh) 2017-11-14
ES2455544T3 (es) 2014-04-16
CA2768938A1 (en) 2011-01-27
JP2015109853A (ja) 2015-06-18
PL2770061T3 (pl) 2019-02-28
SI2770061T1 (sl) 2019-02-28
DK2456786T4 (en) 2017-08-07
EP2456786A1 (en) 2012-05-30
KR101790187B1 (ko) 2017-10-25
ES2702274T3 (es) 2019-02-28
JP2013500015A (ja) 2013-01-07
DK2456786T3 (en) 2014-03-24
AU2010276194A1 (en) 2011-11-24
IL217679A (en) 2016-09-29
CN102482329A (zh) 2012-05-30
NZ597804A (en) 2013-10-25
HRP20140327T1 (hr) 2014-05-09
KR20120068838A (ko) 2012-06-27
AU2010276194B2 (en) 2012-02-02
WO2011011584A1 (en) 2011-01-27
HRP20140327T4 (hr) 2017-11-03
US20110064763A1 (en) 2011-03-17
SG177744A1 (en) 2012-02-28

Similar Documents

Publication Publication Date Title
EP2614140B8 (en) Mdck-derived cell lines adapted to serum-free culture and suspension culture and method for preparing vaccine virus using the cells
WO2012031263A3 (en) Cell culture system for bioreactor scale-up of cells
WO2012045082A3 (en) Engineered nucleic acids and methods of use thereof
TR201906398T4 (tr) Salgı bezleriyle ilişkili virüs yapılarını içeren iletken hava yolu hücrelerinin hedeflenmesine yönelik bileşimler.
BR112014002401A2 (pt) polipeptídeo e polinucleotídeo isolados, composição, construto de ácido nucléico ou vetor de expressão, célula hospedeira recombinante, métodos para produzir o polipeptídeo, e um polipeptídeo, planta transgência, e, processos para degradar um material celulósico ou material contendo xilano, para produzir um produto de fermentação, e para fermentar um material celulósico ou material contendo xilano
WO2012135805A3 (en) Delivery and formulation of engineered nucleic acids
WO2010129602A3 (en) Cocal vesiculovirus envelope pseudotyped retroviral vectors
BR112014000143A2 (pt) variante alfa-amilase, polinucleotídeo isolado, construção de ácido nucleico, vetor de expressão, célula hospedeira, métodos de produzir uma variante de alfa-amilase, para produzir um produto de fermentação a partir de um material contendo amido, e, para a produção um derivado de amido enzimaticamente modificado
BRPI0810418A2 (pt) Membros de ligação alvo, ácido nucléico isolado, vetor de expressão, célula hospedeira, composição, métodos para produzir um membro de ligação alvo, para o tratamento ou prevenção de asma e para produzir um anticorpo contra il-25
WO2013152051A3 (en) Improved production of fatty acid derivatives
EP2663336A1 (en) Methods and reagents for efficient and targeted delivery of therapeutic molecules to cxcr4 cells
BR112014007115A2 (pt) éster sintases de cera acil-acp
AR089440A1 (es) Procesos que emplean particulas similares a virus (psv) con capsides resistentes a hidrolasas
BR112014002405A2 (pt) polopeptídeo e polinucleotídeo isolados, composição, construto de ácido nucleico ou vetor de expressão, célula hospedeira recombinante, planta transgênica, parte da planta ou célula de planta, métodos para produzir um polipeptídeo e uma proteína, e, processos para degradar um material celulóssico, para produzir um produto de fermentação, e para fermentar um material celulósico
WO2010088565A8 (en) Nucleic acid delivery using modified chitosans
BR112014005873A2 (pt) enzimas, constructo de dna, vetor de expressão, célula, preparação, composição, uso e produto
CL2014002018A1 (es) Molécula de ácido nucleico que comprende una secuencia sintética variante de la enzima 5-enolpiruvil shikimato-3-fosfato sintasa para expresión en una planta; vector; célula huesped; método para producir una planta resistente al glifosato y métodos asociados.
WO2008153725A3 (en) Viral nanoparticle cell-targeted delivery platform
BR112014007474A2 (pt) aumento de rendimento de partícula tipo vírus em plantas
Shirvani et al. RETRACTED: Non-coding RNA in SARS-CoV-2: Progress toward therapeutic significance
WO2011115810A3 (en) Isoform-specific rnai based on codon redundancy/degeneracy
WO2010109176A3 (en) Parenteral pharmaceutical composition for use in gene therapy
ZA201307069B (en) Combined cell based gp96-ig-siv/hiv, recombinant gp120 protein vaccination for protection from siv/hiv
NZ617808A (en) Shark-like chondroitin sulphate and process for the preparation thereof
BRPI1014942A2 (pt) "polipeptídeo, ácido nucleico, vetor, célula hospedeira, método para produzir um polipeptídeo, composição farmacêutica, e método para tratar uma doença"

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 14A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2784 DE 14-05-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.